4.5 Review

Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe

Journal

VACCINE
Volume 33, Issue 42, Pages 5520-5531

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.08.020

Keywords

Rift valley fever; Virus; Vaccine

Funding

  1. UK Department for Environment, Food and Rural Affairs (Defra) [SV3045, SE4112]
  2. European Commission Seventh Framework Programme under ANTIGONE [278976]

Ask authors/readers for more resources

Rift Valley fever virus (RVFV) is a mosquito-borne virus, and is the causative agent of Rift Valley fever (RVF), a zoonotic disease characterised by an increased incidence of abortion or foetal malformation in ruminants. Infection in humans can also lead to clinical manifestations that in severe cases cause encephalitis or haemorrhagic fever. The virus is endemic throughout much of the African continent. However, the emergence of RVFV in the Middle East, northern Egypt and the Comoros Archipelago has highlighted that the geographical range of RVFV may be increasing, and has led to the concern that an incursion into Europe may occur. At present, there is a limited range of veterinary vaccines available for use in endemic areas, and there is no licensed human vaccine. In this review, the methods available for diagnosis of RVFV infection, the current status of vaccine development and possible implications for RVFV emergence in Europe, are discussed. Crown Copyright (C) 2015 Published by Elsevier Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available